Description
Rimonabant is the world’s first type 1 cannabinoid receptor (CB1) inhibitor weight-loss drug. smoking cessation effect. As a new weight-loss drug, it was approved for marketing in the European Union in 2006.
Mechanism
One of the most promising of these is rimonabant (Acomplia), which acts on a protein in brain cells called endo-emodin. Endo-emodin has a structure similar to marijuana (cannabis) and may be involved in appetite control. Rimonabant blocks the binding between endo-emodin and its receptors in the brain. (See the study: Marijuana-like substances control appetite for more information.) The drug works by blocking this protein to reduce appetite.
